Review of: "[Review Article] Pitavastatin: A Comprehensive Overview of its Mechanisms, Pharmacokinetics, Pharmacodynamics, and Adverse Effects"

Stefano Bellosta[1]

1 University of Milan

Potential competing interests: No potential competing interests to declare.

I have read the article “Pitavastatin: A Comprehensive Overview of its Mechanisms, Pharmacokinetics, Pharmacodynamics, and Adverse Effects” by Priyanka Chaurasiya, Md Sohel Ahmed, Sarita Sharma, Imran Khan.

Overall, this review article needs a profound revision, both for the language used and the topics.

I know I’m supposed to be kind in giving my comments, but unfortunately, the text is badly written and constructed. There are too many phrases that seem to be just copied from the literature and not revised appropriately. Examples: The authors write: “Pitavastatin would be a great imaging agent for hOATP, which is why we looked at making this agent synthetic [28]”. However, they are not the authors of the paper referenced.

Another example: “we used two methods to validate OATP2B1's negligible role in the liver's absorption of pitavastatin [34].” Again, different authors.

Many phrases are repeated several times, without a meaning. Example: Fungal-derived inhibitors of HMG-CoA reductase, including Lovastatin, Pravastatin, and Simvastatin, and wholly synthetized molecules, including Atorvastatin, Cerivastatin, Fluvastatin, Pravastatin, Pitavastatin, and Rosuvastatin [12], are known. Another new HMG-CoA reductase inhibitor that has demonstrated significant effects on lowering plasma total cholesterol and triglycerides is Pitavastatin [14].

It looks like a collection of phrases taken from different papers, but without trying to organize them into a constructive paper. No new data are provided or commented on.

Other phrases are inserted in the wrong paragraphs: In paragraph 5.1, which deals with patients with dyslipidemia, the authors write: Against approximately 89% of the studied strains, pitavastatin demonstrated broad-spectrum synergistic interactions with both voriconazole and fluconazole. Why strains if they are talking about patients?

In paragraph 5.2, the treatment outcome was sustained for more than 3 weeks, according to the pharmacodynamic investigation conducted in hyperlipidemic rats. Why rats in this paragraph on patients with diabetes?

Authors should define the abbreviations the first time they use them and then use only the abbreviations. Please define DDI, PVTS.

I assume that the phrase: “and promotes adoption” should be “promotes the uptake…”

What do these mean?:

Data from both inside and outside of living organisms; experiments…

- ….which impairs the function of ß-cells and reduces their sensitivity to insulin and release of it…
- …Pitavastatin is thought to have a lower effect on LDL-C because of its longer half-life when compared to other statins …
- …Pitavastatin is a new type of statin that causes plaque regression. It is not worse than atorvastatin and….

The passage of PVTS…. Does this mean the absorption of pitavastatin??

Sick individuals are called patients.

I do not understand this: Pitavastatin, the only lipid-lowering research with statins, has shown a correlation between drug-induced increases in HDL-C and decreased cardiovascular risk.

Other phrases without meaning:

- It shows that using two extracts, PTVS exposes the cell feasibility: sunflower oil, which dramatically restored the action of PTVS in cell proliferation, and milk, which cannot verify that the results in the assay reflected cell death.
- Few studies suggest that using statins causes skeletal muscle contractions to behave favourably.
- HMG coenzyme hydroxymethyl One of the drugs that doctors prescribe most frequently in Asia is a reductase (HMGCoA) inhibitor, sometimes known as a statin